Parenteral Nutrition and Cardiotoxicity.
Endothelial nitric oxide synthase
Parenteral nutrition
Reactive oxygen species
Tetrahydrobiopterin
Journal
Cardiovascular toxicology
ISSN: 1559-0259
Titre abrégé: Cardiovasc Toxicol
Pays: United States
ID NLM: 101135818
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
04
11
2020
accepted:
27
01
2021
pubmed:
9
2
2021
medline:
15
12
2021
entrez:
8
2
2021
Statut:
ppublish
Résumé
Parenteral nutrition (PN) is a life-saving nutritional therapy for those situations when patients are unable to receive enteral nutrition. However, despite a multitude of benefits offered by PN, it is associated with a variety of side effects, most notably parenteral nutrition-associated liver disease (PNALD). Adverse effects of PN on other organ systems, such as brain and cardiovascular system, have been poorly studied. There have been several case reports, studies, and a recent animal study highlighting cardiotoxic effects of PN; however, much remains unclear about the underlying mechanisms causing cardiac damage. In this review, we propose a series of potential mechanisms behind PN-associated heart injury, and we provide an overview of therapeutic strategies and recent scientific advances.
Identifiants
pubmed: 33554318
doi: 10.1007/s12012-021-09638-1
pii: 10.1007/s12012-021-09638-1
doi:
Substances chimiques
Antioxidants
0
GPBAR1 protein, human
0
Reactive Oxygen Species
0
Receptors, G-Protein-Coupled
0
Biopterins
0
sapropterin
EGX657432I
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
265-271Subventions
Organisme : NIBIB NIH HHS
ID : R03 EB015955
Pays : United States
Organisme : NIDDK NIH HHS
ID : K08 DK098623
Pays : United States
Références
Chowdary, K. V., & Reddy, P. N. (2010). Parenteral nutrition: Revisited. Indian Journal of Anaesthesia, 54(2), 95–103.
pubmed: 20661345
pmcid: 2900762
Xu, Z. W., & Li, Y. S. (2012). Pathogenesis and treatment of parenteral nutrition-associated liver disease. Hepatobiliary & Pancreatic Diseases International, 11(6), 586–593.
Martinez, M., & Ballabriga, A. (1987). Effects of parenteral nutrition with high doses of linoleate on the developing human liver and brain. Lipids, 22(3), 133–138.
pubmed: 3106740
Bertinet, D. B., et al. (2000). Brain manganese deposition and blood levels in patients undergoing home parenteral nutrition. JPEN Journal of Parenteral and Enteral Nutrition, 24(4), 223–227.
pubmed: 10885716
Hayes, B. D., et al. (2016). Systematic review of clinical adverse events reported after acute intravenous lipid emulsion administration. Clinical Toxicology (Philadelphia, PA), 54(5), 365–404.
Abel, R. M., Fisch, D., & Grossman, M. L. (1983). Hemodynamic effects of intravenous 20% soy oil emulsion following coronary bypass surgery. JPEN Journal of Parenteral and Enteral Nutrition, 7(6), 534–540.
pubmed: 6418908
Suchner, U., et al. (2001). Effects of intravenous fat emulsions on lung function in patients with acute respiratory distress syndrome or sepsis. Critical Care Medicine, 29(8), 1569–1574.
pubmed: 11505129
Marfella, R., et al. (2001). Elevated plasma fatty acid concentrations prolong cardiac repolarization in healthy subjects. American Journal of Clinical Nutrition, 73(1), 27–30.
Barson, A. J., Chistwick, M. L., & Doig, C. M. (1978). Fat embolism in infancy after intravenous fat infusions. Archives of Disease in Childhood, 53(3), 218–223.
pubmed: 417679
pmcid: 1545144
Hulman, G., & Levene, M. (1986). Intralipid microemboli. Archives of Disease in Childhood, 61(7), 702–703.
pubmed: 3740913
pmcid: 1777900
Cole, J. B., Stellpflug, S. J., & Engebretsen, K. M. (2014). Asystole immediately following intravenous fat emulsion for overdose. Journal of Medical Toxicology, 10(3), 307–310.
pubmed: 24519703
pmcid: 4141925
Naidoo, D. P., Singh, B., & Haffejee, A. (1992). Cardiovascular complications of parenteral nutrition. Postgraduate Medical Journal, 68(802), 629–633.
pubmed: 1448402
pmcid: 2399567
Naidoo, D. P., et al. (1989). Acute pernicious beriberi in a patient receiving parenteral nutrition. A case report. South African Medical Journal, 75(11), 546–548.
pubmed: 2499068
Warren, M., et al. (2013). Pericardial effusion and cardiac tamponade in neonates: Sudden unexpected death associated with total parenteral nutrition via central venous catheterization. Annals of Clinical and Laboratory Science, 43(2), 163–171.
pubmed: 23694791
Demircan, M., et al. (2015). Damaging effects of total parenteral nutrition formula on vascular endothelium. Journal of Pediatric Gastroenterology and Nutrition, 61(4), 464–468.
pubmed: 25905544
Hagiwara, S., et al. (2008). Effect of enteral versus parenteral nutrition on inflammation and cardiac function in a rat model of endotoxin-induced sepsis. Shock, 30(3), 280–284.
pubmed: 18197141
Gurunluoglu, K., et al. (2020). Investigation of the cardiotoxic effects of parenteral nutrition in rabbits. Journal of Pediatric Surgery, 55(3), 465–474.
pubmed: 31109733
Hasanoglu, A., et al. (2005). Free oxygen radical-induced lipid peroxidation and antioxidant in infants receiving total parenteral nutrition. Prostaglandins Leukotrienes and Essential Fatty Acids, 73(2), 99–102.
Ma, J., et al. (2018). Hyperglycemia is associated with cardiac complications in elderly nondiabetic patients receiving total parenteral nutrition. Medicine (Baltimore), 97(6), e9537.
Gosmanov, A. R., & Umpierrez, G. E. (2013). Management of hyperglycemia during enteral and parenteral nutrition therapy. Current Diabetes Reports, 13(1), 155–162.
pubmed: 23065369
pmcid: 3746491
Lee, H., Koh, S. O., & Park, M. S. (2011). Higher dextrose delivery via TPN related to the development of hyperglycemia in non-diabetic critically ill patients. Nutrition Research Practice, 5(5), 450–454.
pubmed: 22125683
Cheung, N. W., et al. (2005). Hyperglycemia is associated with adverse outcomes in patients receiving total parenteral nutrition. Diabetes Care, 28(10), 2367–2371.
pubmed: 16186264
Lin, L. Y., et al. (2007). Hyperglycemia correlates with outcomes in patients receiving total parenteral nutrition. American Journal of the Medical Sciences, 333(5), 261–265.
Korshunov, S. S., Skulachev, V. P., & Starkov, A. A. (1997). High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Letters, 416(1), 15–18.
pubmed: 9369223
Brownlee, M. (2005). The pathobiology of diabetic complications: A unifying mechanism. Diabetes, 54(6), 1615–1625.
Volpe, C. M. O., et al. (2018). Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death & Disease, 9(2), 119.
Nogueira-Machado, J. A., & Chaves, M. M. (2008). From hyperglycemia to AGE-RAGE interaction on the cell surface: A dangerous metabolic route for diabetic patients. Expert Opinion on Therapeutic Targets, 12(7), 871–882.
pubmed: 18554155
Krakauer, T. (2015). Inflammasome, mTORC1 activation, and metabolic derangement contribute to the susceptibility of diabetics to infections. Medical Hypotheses, 85(6), 997–1001.
pubmed: 26384528
Mount, P. F., Kemp, B. E., & Power, D. A. (2007). Regulation of endothelial and myocardial NO synthesis by multi-site eNOS phosphorylation. Journal of Molecular and Cellular Cardiology, 42(2), 271–279.
pubmed: 16839566
Siragusa, M., & Fleming, I. (2016). The eNOS signalosome and its link to endothelial dysfunction. Pflugers Archiv European Journal of Physiology, 468(7), 1125–1137.
pubmed: 27184745
Cosentino, F., et al. (1997). High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation, 96(1), 25–28.
pubmed: 9236411
Katusic, Z. S. (2001). Vascular endothelial dysfunction: Does tetrahydrobiopterin play a role? American Journal of Physiology-Heart and Circulatory Physiology, 281(3), H981–H986.
pubmed: 11514262
Gebhart, V., et al. (2019). Site and mechanism of uncoupling of nitric-oxide synthase: Uncoupling by monomerization and other misconceptions. Nitric Oxide, 89, 14–21.
pubmed: 31022534
Fiorentino, T. V., et al. (2013). Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Current Pharmaceutical Design, 19(32), 5695–5703.
pubmed: 23448484
Yuyun, M. F., Ng, L. L., & Ng, G. A. (2018). Endothelial dysfunction, endothelial nitric oxide bioavailability, tetrahydrobiopterin, and 5-methyltetrahydrofolate in cardiovascular disease. Where are we with therapy? Microvascular Research, 119, 7–12.
pubmed: 29596860
Knowles, R. G., & Moncada, S. (1994). Nitric oxide synthases in mammals. The Biochemical Journal, 298(Pt 2), 249–258.
pubmed: 7510950
pmcid: 1137932
Soskić, S. S., et al. (2011). Regulation of inducible nitric oxide synthase (iNOS) and its potential role in insulin resistance, diabetes and heart failure. The Open Cardiovascular Medicine Journal, 5, 153–163.
pubmed: 21792376
pmcid: 3141344
Yang, P., Cao, Y., & Li, H. (2010). Hyperglycemia induces inducible nitric oxide synthase gene expression and consequent nitrosative stress via c-Jun N-terminal kinase activation. American Journal of Obstetrics and Gynecology, 203(2), 185.e5–11.
McNeill, E., et al. (2015). Regulation of iNOS function and cellular redox state by macrophage Gch1 reveals specific requirements for tetrahydrobiopterin in NRF2 activation. Free Radical Biology Medicine, 79, 206–216.
pubmed: 25451639
pmcid: 4344222
Huisman, A., et al. (2002). Anti-inflammatory effects of tetrahydrobiopterin on early rejection in renal allografts: Modulation of inducible nitric oxide synthase. The FASEB Journal, 16(9), 1135–1137.
pubmed: 12039851
Xia, Y., et al. (1998). Inducible nitric-oxide synthase generates superoxide from the reductase domain. Journal of Biological Chemistry, 273(35), 22635–22639.
Lind, M., et al. (2017). Inducible nitric oxide synthase: Good or bad? Biomedicine & Pharmacotherapy, 93, 370–375.
Fujimoto, M., et al. (2005). A role for iNOS in fasting hyperglycemia and impaired insulin signaling in the liver of obese diabetic mice. Diabetes, 54(5), 1340–1348.
pubmed: 15855318
Konstantoulaki, M., Kouklis, P., & Malik, A. B. (2003). Protein kinase C modifications of VE-cadherin, p120, and beta-catenin contribute to endothelial barrier dysregulation induced by thrombin. American Journal of Physiology. Lung Cellular and Molecular Physiology, 285(2), L434–L442.
pubmed: 12740216
Di, A., Mehta, D., & Malik, A. B. (2016). ROS-activated calcium signaling mechanisms regulating endothelial barrier function. Cell Calcium, 60(3), 163–171.
pubmed: 26905827
pmcid: 4988951
Ide, T., et al. (2001). Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circulation Research, 88(5), 529–535.
pubmed: 11249877
Pacher, P., & Szabó, C. (2006). Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Current Opinion in Pharmacology, 6(2), 136–141.
pubmed: 16483848
pmcid: 2228269
Lum, H., & Roebuck, K. A. (2001). Oxidant stress and endothelial cell dysfunction. American Journal of Physiology. Cell Physiology, 280(4), C719–C741.
pubmed: 11245588
Pacher, P., et al. (2005). Nitrosative stress and pharmacological modulation of heart failure. Trends in Pharmacological Sciences, 26(6), 302–310.
pubmed: 15925705
pmcid: 2228264
Kar, S., et al. (2010). Redox-control of matrix metalloproteinase-1: A critical link between free radicals, matrix remodeling and degenerative disease. Respiratory Physiology & Neurobiology, 174(3), 299–306.
Kim, H. E., et al. (2000). Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. Journal of Clinical Investigation, 106(7), 857–866.
pmcid: 517818
Verma, S., et al. (2002). Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: Identifying cellular targets for pharmacologic manipulation. Journal of Thoracic and Cardiovascular Surgery, 123(6), 1074–1083.
Bendall, J. K., et al. (2014). Tetrahydrobiopterin in cardiovascular health and disease. Antioxidants & Redox Signaling, 20(18), 3040–3077.
Cai, S., Khoo, J., & Channon, K. M. (2005). Augmented BH4 by gene transfer restores nitric oxide synthase function in hyperglycemic human endothelial cells. Cardiovascular Research, 65(4), 823–831.
pubmed: 15721862
Group, P.-D., et al. (2006). Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 113(12), 2221–2230.
Idris, I., & Donnelly, R. (2006). Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy. Diabetes and Vascular Disease Research, 3(3), 172–178.
pubmed: 17160912
Wilson, C. H., et al. (2015). Steatosis inhibits liver cell store-operated Ca
pubmed: 25422863
Cross, A. R., & Segal, A. W. (2004). The NADPH oxidase of professional phagocytes–prototype of the NOX electron transport chain systems. Biochimica et Biophysica Acta, 1657(1), 1–22.
pubmed: 15238208
pmcid: 2636547
Jaquet, V., et al. (2009). Small-molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxidants & Redox Signaling, 11(10), 2535–2552.
Kahles, T., et al. (2007). NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke, 38(11), 3000–3006.
pubmed: 17916764
Sedeek, M., et al. (2010). Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: Implications in type 2 diabetic nephropathy. American Journal of Physiology. Renal Physiology, 299(6), F1348–F1358.
pubmed: 20630933
Williams, H. C., & Griendling, K. K. (2007). NADPH oxidase inhibitors: New antihypertensive agents? Journal of Cardiovascular Pharmacology, 50(1), 9–16.
pubmed: 17666910
Wang, W., et al. (2017). Rutin protects endothelial dysfunction by disturbing Nox4 and ROS-sensitive NLRP3 inflammasome. Biomedicine & Pharmacotherapy, 86, 32–40.
Gray, S. P., et al. (2017). Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. Diabetologia, 60(5), 927–937.
pubmed: 28160092
Zheng, D., et al. (2015). Exogenous hydrogen sulfide attenuates cardiac fibrosis through reactive oxygen species signal pathways in experimental diabetes mellitus models. Cellular Physiology and Biochemistry, 36(3), 917–929.
pubmed: 26088607
Das, A., et al. (2014). Mammalian target of rapamycin (mTOR) inhibition with rapamycin improves cardiac function in type 2 diabetic mice: Potential role of attenuated oxidative stress and altered contractile protein expression. Journal of Biological Chemistry, 289(7), 4145–4160.
Esteghamati, A., et al. (2013). Effects of metformin on markers of oxidative stress and antioxidant reserve in patients with newly diagnosed type 2 diabetes: A randomized clinical trial. Clinical Nutrition, 32(2), 179–185.
pubmed: 22963881
Chen, Z. H., et al. (2010). Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney International, 77(11), 974–988.
pubmed: 20375980
Fortuno, A., et al. (2009). Losartan metabolite EXP3179 blocks NADPH oxidase-mediated superoxide production by inhibiting protein kinase C: Potential clinical implications in hypertension. Hypertension, 54(4), 744–750.
pubmed: 19687351
Meng, R., et al. (2011). Anti-oxidative effect of apocynin on insulin resistance in high-fat diet mice. Annals of Clinical and Laboratory Science, 41(3), 236–243.
pubmed: 22075506
Taye, A., & Morawietz, H. (2011). Spironolactone inhibits NADPH oxidase-induced oxidative stress and enhances eNOS in human endothelial cells. Iranian Journal of Pharmaceutical Research, 10(2), 329–337.
pubmed: 24250362
Vendrov, A. E., et al. (2010). NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis. Journal of Biological Chemistry, 285(34), 26545–26557.
Duboc, H., Taché, Y., & Hofmann, A. F. (2014). The bile acid TGR5 membrane receptor: From basic research to clinical application. Digstive and Liver Disease, 46(4), 302–312.
Kawamata, Y., et al. (2003). A G protein-coupled receptor responsive to bile acids. Journal of Biological Chemistry, 278(11), 9435–9440.
Maruyama, T., et al. (2006). Targeted disruption of G protein-coupled bile acid receptor 1 (Gpbar1/M-Bar) in mice. Journal of Endocrinology, 191(1), 197–205.
Watanabe, M., et al. (2006). Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature, 439(7075), 484–489.
pubmed: 16400329
Eblimit, Z., et al. (2018). TGR5 activation induces cytoprotective changes in the heart and improves myocardial adaptability to physiologic, inotropic, and pressure-induced stress in mice. Cardiovascular Therapeutics, 36(5), e12462.
pubmed: 30070769
pmcid: 6800140
Kumar, D. P., et al. (2012). Activation of transmembrane bile acid receptor TGR5 stimulates insulin secretion in pancreatic beta cells. Biochemical and Biophysical Research Communications, 427(3), 600–605.
pubmed: 23022524
pmcid: 3498511
Jain, A. K., et al. (2016). Oleanolic acid improves gut atrophy induced by parenteral nutrition. JPEN Journal of Parenteral and Enteral Nutrition, 40(1), 67–72.
pubmed: 25921560
Wang, Y. D., et al. (2011). The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor κ light-chain enhancer of activated B cells (NF-κB) in mice. Hepatology, 54(4), 1421–1432.
pubmed: 21735468
pmcid: 3184183
Perino, A., et al. (2014). TGR5 reduces macrophage migration through mTOR-induced C/EBPβ differential translation. Journal of Clinical Investigation, 124(12), 5424–5436.